Comparison of basal insulin added to oral agents versus twice - daily premixed insulin as initial insulin therapy for type 2 diabetes

Pakistan Journal of Medical Sciences

Volumn 22, Issue 1, 2006, Pages 14-17

  Al Shaikh, Abdul Rehman ^a  

^a KING ABDUL AZIZ UNIVERSITY HOSPITAL   (Saudi Arabia)

Author keywords

Glargine insulin; Insulin; Type II diabetes

Indexed keywords

ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; INSULIN; INSULIN GLARGINE; METFORMIN; SULFONYLUREA;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DRUG EFFICACY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT; TITRIMETRY;

EID: 33644788999     PISSN: 1682024X     EISSN: 1682024X     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Intensive blood - glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. UK Prospective Diabetes Study (UKPDS) Group, Lancet 1998; 352: 837.
2. Standards of medical care in diabetes. Diabetes Care 2004; 27 Suppl 1: S15.
3. Henry RR, Gumbiner B, Ditzler T, Wallace P, Glauber HS. Intensive conventional insulin therapy for type2 diabetes: metabolic effects during a 6-month outpatient trial. Diabetes Care 1993; 16 (1): 21-31.
4. Johnson JL, Wolf SL, Kabadi UM. Efficacy of insulin and sulfonylurea combination therapy in Type-II diabetes: a meta-analysis of the randomized placebocontrolled trials. Arch Intern Med 1996; 156:259.
5. Wright A, Burden AC, Paisey RB, Cull CA, Holman RR. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care 2002; 25: 330.
6. Pugh JA, Wagner ML, Sawyer J, Ramirez G, Tuley M, Friedberg SJ. Is combination of sulfonylurea and insulin therapy useful in NIDDM patients? Ametaanalysis. Diabetes Care 1992; 15: 953.
7. Yki-Jarvinen H, Ryysy L, Nikkila K, Tulokas T, Vanamo R, Heikkila M. Comparison of bed time insulin regimens in patients with type 2 diabetes mellitus. A randomized control trial. Ann Intern Med 1999; 130(5): 389-96.
8. Abraira C, Colwell JA, Nuttall FQ, Sawin CT, Nagel NJ, Comstock JP, et al. Veterans Affairs Cooperative Study on glycemic control and complications in Type-II diabetes (VA CSDM). Results of of the feasibility trial. Diabetes Care 1995; 18: 1113.
9. Yki-Jarvinen H, Kauppila M, Kujansuu E, Lahti J, Marjanen T, Niskanen L, Rajala S et al. Comparison of insulin regimens in patients with insulin dependent diabetes. N Engl J Med 1992; 327: 1426.
10. Chow CC, Tsang LW, Sorensen JP, Cockram CS. Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatments of secondary failure in NIDDM patients. Diabetes Care 1995; 18: 307.
11. Landstedt-Hallin L, Adamson U, Arner P, Bolinder J, Lins PE. Comparison of bed time NPH insulin or preprandial regular insulin combined with glibenclamide in secondary sulfonylurea failure. Diabetes Care 1995; 18: 1183.
12. Schwartz S, Sievers R, Strange P, Lyness WH, Hollander P. Insulin 70/30 mix plus metformin versus triple oral therapy in the treatment of the type 2 diabetes mellitus after failure of two oral drugs: efficacy, safety, and cost analysis. Diabetes Care 2003; 26: 2238.
13. Riddle MC, Rosenstock J, Gerich J. The treat to target trial: randomized addition of Glargine insulin or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003; 26: 3080.
14. Fritsche A, Schweitzer MA, Haring HU. Glimepride combined with morning insulin Glargine, bedtime neutral protamine hagedorn insulin, or bedtime Glargine insulin in patients with type2 diabetes. A randomized, controlled trial. Ann Intern Med 2003; 138: 952.
15. Hans U, Gerd P, Matthew C R, Christine K F, Matthias A, Schweitzer et al. Comparison of basal insulin added to oral agents versus twice daily premixed insulin as initial insulin therapy for type2 diabetes. Diabetes Care 2005; 28: 254-9.